Skip to main content
CLRB
NASDAQ Life Sciences

COO Buys $25K in Stock and Warrants Amidst Recent Dilution and Going Concern Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.92
Mkt Cap
$12.975M
52W Low
$2.43
52W High
$20.595
52W Position info
20% above low
Off High info
86% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

CLRB sits 20% above its 52-week low of $2.43 on light trading volume (0.3× avg).

Summary

Cellectar Biosciences' COO purchased over $25,000 in company stock and warrants, signaling confidence after recent dilutive financing and a going concern warning.


Key Events · Ownership and Investor Activity · CLRB

  • COO Open Market Purchase

    Jarrod Longcor, Chief Operating Officer, acquired 34,720 shares of common stock and 26,040 warrants for a total of $25,259 on the open market.

  • Confidence Amidst Financial Challenges

    This purchase on May 7th directly follows the company's recent highly dilutive $35 million offering and a prior "going concern" warning, indicating a vote of confidence from a key executive despite significant financial headwinds.


Analysis · CLRB · Life Sciences

Chief Operating Officer Jarrod Longcor made an open market purchase of common stock and warrants totaling $25,259. This insider buying provides a positive signal, especially as it occurred on May 7th, immediately following the company's highly dilutive $35 million registered direct offering and private placement, and after a previous disclosure of substantial doubt about its ability to continue as a going concern. The purchase suggests management confidence despite these significant financial challenges.

How filings like this one have moved

In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CLRB was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $2.43 to $20.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CLRB - Latest Insights

CLRB
Sep 29, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $1.84 info
Change: +$0.0405 (+2%) info
Market Cap: $17.392M info
CLRB
Aug 13, 2026, 7:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $1.84 info
Change: -$0.760 (-29%) info
Market Cap: $17.392M info
CLRB
Aug 13, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $1.84 info
Change: -$0.760 (-29%) info
Market Cap: $17.392M info
CLRB
Aug 13, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $1.84 info
Change: -$0.760 (-29%) info
Market Cap: $17.392M info
CLRB
Jul 10, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $1.84 info
Change: -$0.980 (-35%) info
Market Cap: $17.392M info